共 13 条
[1]
[2]
[3]
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive; Estrogen Receptor–Negative Metastatic Breast Cancer.[J].Ayca Gucalp;Sara Tolaney;Steven J. Isakoff;James N. Ingle;Minetta C. Liu;Lisa A. Carey;Kimberly Blackwell;Hope Rugo;Lisle Nabell;Andres Forero;Vered Stearns;Ashley S. Doane;Michael Danso;Mary Ellen Moynahan;Lamia F. Momen;Joseph M. Gonzalez;Arooj Akhtar;Dilip D. Giri;Sujata Patil;Kimberly N. Feigin;Clifford A. Hudis;Tiffany A. Traina.Clinical Cancer Research.2013, 1
[5]
The AR dependent cell cycle: Mechanisms and cancer relevance.[J].Matthew J. Schiewer;Michael A. Augello;Karen E. Knudsen.Molecular and Cellular Endocrinology.2011, 1-2
[9]
Antiproliferative actions of the synthetic androgen; mibolerone; in breast cancer cells are mediated by both androgen and progesterone receptors.[J].Elisa J. Cops;Tina Bianco-Miotto;Nicole L. Moore;Christine L. Clarke;Stephen N. Birrell;Lisa M. Butler;Wayne D. Tilley.Journal of Steroid Biochemistry and Molecular Biology.2008, 3
[10]
A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer
[J].
NEOPLASIA,
2008, 10 (06)
:542-548

